文献速递肿瘤 PET/CT

PET/CT与PET/MRI在卵巢癌中作用的最新进展

An update on the role of PET/CT and PET/MRI in ovarian cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-02-08

本文综述PET/CT与PET/MRI在卵巢癌中的应用。FDG PET/CT对淋巴结和远处转移检测准确性高,可能改变治疗决策以获更好临床结局,但对T分期作用有限。FDG PET/CT在疗效评估和复发检测中有价值,尤其血清CA-125升高而常规影像阴性或不确定时。PET/MRI因软组织对比度更高且无电离辐射,可能有助于肿瘤分期。

要点

  • 绝经后女性卵巢FDG摄取增高需警惕卵巢癌。
  • FDG PET/CT对卵巢癌N和M分期优于T分期。
  • FDG PET/CT在疗效评估、预后判断及复发检测中有价值。

核心结论

  • FDG PET/CT可高准确度检测卵巢癌淋巴结和远处转移,可能改变治疗决策以获更好临床结局,但对T分期作用有限。
  • FDG PET/CT在疗效评估和预后判断中有重要价值,并可用于检测复发,尤其血清CA-125升高而常规影像阴性或不确定时。
  • PET/MRI因MRI软组织对比度更高且无电离辐射,可能有助于肿瘤分期。
  • 18F-氟胸腺嘧啶(FLT)或11C-蛋氨酸(MET)等非FDG示踪剂已在临床前和临床研究中探索,可能在卵巢癌评估中发挥作用。

研究设计与样本

  • 本文为综述文章,总结PET/CT与PET/MRI在卵巢癌中的作用。

主要发现

  • 绝经后女性卵巢内出现FDG摄取增高需警惕卵巢癌。
  • 多项研究显示FDG PET/CT可高准确度检测卵巢癌淋巴结和远处转移,可能改变治疗决策以获更好临床结局。
  • FDG PET/CT对卵巢癌N和M分期优于T分期。
  • FDG PET/CT在疗效评估中有重要价值,并具有预后价值。
  • FDG PET/CT可检测复发,尤其血清CA-125升高而常规影像阴性或不确定时。

关键数值与推荐

  • FDG PET/CT对卵巢癌N和M分期优于T分期。
  • FDG PET/CT可高准确度检测淋巴结和远处转移。
  • PET/MRI因软组织对比度更高且无电离辐射,可能有助于肿瘤分期。
  • 18F-FLT或11C-MET等非FDG示踪剂已在临床前和临床研究中探索,可能在卵巢癌评估中发挥作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review article summarizes the role of PET/CT and PET/MRI in ovarian cancer. With regard to the diagnosis of ovarian cancer, the presence of FDG uptake within the ovary of a postmenopausal woman raises the concern for ovarian cancer. Multiple studies show that FDG PET/CT can detect lymph node and distant metastasis in ovarian cancer with high accuracy and may, therefore, alter the management to obtain better clinical outcomes. Although PET/CT staging is superior for N and M staging of ovarian cancer, its role is limited for T staging. Additionally, FDG PET/CT is of great benefit in evaluating treatment response and has prognostic value in patients with ovarian cancer. FDG PET/CT also has value to detect recurrent disease, particularly in patients with elevated serum CA-125 levels and negative or inconclusive conventional imaging test results. PET/MRI may beneficial for tumor staging because MRI has higher soft tissue contrast and no ionizing radiation exposure compared to CT. Some non-FDG PET radiotracers such as 18F-fluorothymidine (FLT) or 11C-methionine (MET) have been studied in preclinical and clinical studies as well and may play a role in the evaluation of patients with ovarian cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Khiewvan B, Torigian DA, Emamzadehfard S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28180966. doi:10.1007/s00259-017-3638-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。